Horizon Discovery Group Plc Launches Gene-Engineered Bioproduction Cell Line with Flexible Licensing Model

Horizon Discovery Group has announced that its bioproduction division has shipped its first commercially available engineered CHO cell line for use in manufacturing of therapeutic antibodies. Horizon’s innovative licensing model brings these cutting edge bioproduction cells within reach of companies of all sizes, reducing timelines and costs associated with the development of large molecule drugs (biotherapeutics). The product represents a new revenue stream for the company in a business area that is anticipated will be a further driver of growth going forward.
Cell line development for the manufacturing of biotherapeutics was not envisaged as a significant revenue stream at the time of Horizon’s IPO, but has since emerged as a significant opportunity allowing the company to tap into a biomanufacturing market valued at £1.8 billion in 2012 and anticipated to grow to £2.9 billion by 2017.
The Glutamine Synthetase GS system is currently the industry gold standard as it enables use of a metabolic selection process without the need for chemical inhibitors, which are both toxic and expensive. This in turn reduces the timelines associated with identifying specific cells that produce high levels of the biotherapeutic. Access to state of the art cell lines for biomanufacturing has previously been limited by high costs and restrictive licensing conditions. Horizon is adopting a flexible new licensing model with simplified terms and no associated royalties, enabling companies of all sizes to be able to improve their upstream bioprocessing.
This latest development is the first step in Horizon’s strategy towards building a comprehensive GMP bioproduction cell line platform.
Dr Brian Burke, Business Development Director, Horizon Discovery Group, said: “Cell line development has until now been a rate limiting step for improving upstream bioprocessing, particularly for challenging biomolecules. We see this as a key step to drive the potential for personalized medicine.”
Dr Darrin M. Disley, CEO of Horizon Discovery Group, added: “This work, based on a previously announced partnership with a major pharmaceutical partner, is a further example of how Horizon leverages customer projects and grant funding to generate revenue, profit and milestones for the business.”
Related News
-
News CPHI Online Trend Report – 2025 Pharma Packaging Prospects
The pharmaceutical packaging market has seen marked shifts in innovations, priorities, and focus over the last few years. With the rise of hit drugs like GLP-1 agonists and biologics requiring specialised packaging considerations, the strain of meeting... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance